MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ.
The new headquarters will be occupied in mid-May and is a key step towards the achievement of several corporate initiatives, including improving the efficiency of the Company’s operational infrastructure by consolidating office locations and hiring and retaining experienced employees. The Company has shifted its emphasis from horizontal integration to focusing on its core sales and marketing strengths to build a leading specialty pharmaceutical business.
Commenting on the new headquarters, Doug Drysdale, President and CEO of Pernix said, “Establishing Pernix’s headquarters in Morristown, New Jersey continues our efforts to build Pernix into a focused specialty pharmaceutical company with an experienced management team that is well-positioned for additional product acquisitions.”
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia and KHEDEZLA, a treatment for major depressive disorder. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is now based in Morristown, New Jersey.
Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.